Novasenta Inc.

PITTSBURGH, PA · Founded 2018 · CIK 0001936994 · Medtech

Acoustic biomarker detection platform for early disease diagnosis

novasenta.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$25M
2 Form D · Feb 2024
32 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$10,000,000
Private capital raisedForm D · SEC$15,000,000
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1470PEARL DIAGNOSTICS, INC.—$15M
1471KULEANA TECHNOLOGY, INC.—$250K
1472MAINELY SENSORS, LLC——
1473Novasenta Inc.—$25M
1474Neurosity, Inc.—$5.0M
1475Nanopath—$15M
1476BoldHue, Inc.—$3.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Jeanne CunicelliDirector
  • Greg DelgoffeDirector
  • Matthias KleinzDirector
  • Mani MohindruDirector · Executive Officer
  • David MooreDirector

Patents

USPTO · 0 granted of 3
  • ANTI-CD161 Antibodies And Methods Of Use Thereofapplication
  • ANTI-CD161 Antibodies And Methods Of Use Thereofapplication
  • ANTI-CD161 Antibodies And Methods Of Use Thereofapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.